Heshmatpour Amir F purchased $39K of NTHI

Heshmatpour Amir F (CEO, President) purchased 10,000 shares of NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) at $3.86 on 2026-11-09.

Original reporting
SEC EDGAR · Heshmatpour Amir F
Published Nov 10, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 12:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTHI
Neutral
high confidence
Mentioned
$NTHI
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTHINeutralLow
01

Why it matters

The filing adds a new data point on insider ownership but is too small to affect pricing.

02

Market read

A modest insider purchase that provides a fresh but low‑impact data point for traders.

03

What to watch

Potential upcoming corporate actions not disclosed could motivate the buy.

Relevance 4/10Novelty 3/10Timing: filing released after market close on 2026‑11‑09

Background

Form 4 filings disclose insider transactions and are used to gauge insider sentiment.

Company-level read

Ticker impact

$NTHINeutralHigh confidence
Context

CEO Amir Heshmatpour bought 10,000 shares for $38,600, raising his stake to 3.263M shares.

Expected impact

slight upward pressure, likely negligible impact

Evidence & confidence

The transaction is a primary Form 4 filing, but the $38.6k amount is trivial for a mid‑cap issuer.

Market effects

No material effect on the technology sector.

Limited to US investors tracking insider activity.

None

Counterpoint

The purchase could be a routine portfolio rebalancing, not a bullish signal.

Key entities

  • Neonc Technologies Holdings, Inc.

    Issuer of the Form 4 filing.

  • Amir Heshmatpour

    CEO and director of Neonc Technologies, reported the purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTHIMedAI 8/10

NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Updated NEO100 Phase 1/2a results and NEO212 Phase 1 data to be presented at the Society for Neuro-Oncology Annual Meeting on November 13 CALABASAS, Calif., Nov.

$NTHIMedAI 8/10

NeOnc to Present NEO100 and NEO212 Data at Neuro-Oncology Meeting

NeOnc Technologies (NTHI) will present data on its NEO100 and NEO212 programs at the Society for Neuro-Oncology meeting. NEO100 data includes Phase 1/2a study and compassionate use results for recurrent IDH1-mutant astrocytoma. NEO212 data covers Phase 1 safety, pharmacokinetics, and early activity signals in TMZ-resistant recurrent GBM and brain metastases. Both posters are scheduled for November 13, 2026.

$NTHILowAI 8/10

NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi Treating physicians report that a critically ill three-year-old boy is breathing independently and showing renewed movement following initiation of invest